Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches

Girigoswami, Koyeli; Arunkumar, Radhakrishnan; Girigoswami, Agnishwar

doi:10.1080/07853890.2024.2352022

Cited by 1 publication

(1 citation statement)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, urate-lowering therapy appears to be a feasible treatment option for hyperuricemia with concomitant cardiovascular disease ( 9 ). Lowering uric acid levels is considered a method to optimize blood pressure regulation ( 10 ). Additionally, urate-lowering treatment with allopurinol can inhibit the renal reabsorption of uric acid, providing protection to the kidneys ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Causal impact of human blood metabolites and metabolic pathways on serum uric acid and gout: a mendelian randomization study

Zhong,

Yang,

Zhang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveHyperuricaemia and gout are common metabolic disorders. However, the causal relationships between blood metabolites and serum urate levels, as well as gout, remain unclear. A systematic evaluation of the causal connections between blood metabolites, hyperuricemia, and gout could enhance early screening and prevention of hyperuricemia and gout in clinical settings, providing novel insights and approaches for clinical treatment.MethodsIn this study, we employed a bidirectional two-sample Mendelian randomization analysis utilizing data from a genome-wide association study involving 7,286 participants, encompassing 486 blood metabolites. Serum urate and gout data were sourced from the Chronic Kidney Disease Genetics consortium, including 288,649 participants for serum urate and 9,819 African American and 753,994 European individuals for gout. Initially, LDSC methodology was applied to identify blood metabolites with a genetic relationship to serum urate and gout. Subsequently, inverse-variance weighting was employed as the primary analysis method, with a series of sensitivity and pleiotropy analyses conducted to assess the robustness of the results.ResultsFollowing LDSC, 133 blood metabolites exhibited a potential genetic relationship with serum urate and gout. In the primary Mendelian randomization analysis using inverse-variance weighting, 19 blood metabolites were recognized as potentially influencing serum urate levels and gout. Subsequently, the IVW p-values of potential metabolites were corrected using the false discovery rate method. We find leucine (IVW P FDR = 0.00004), N-acetylornithine (IVW P FDR = 0.0295), N1-methyl-3-pyridone-4-carboxamide (IVW P FDR = 0.0295), and succinyl carnitine (IVW P FDR = 0.00004) were identified as significant risk factors for elevated serum urate levels. Additionally, 1-oleoylglycerol (IVW P FDR = 0.0007) may lead to a substantial increase in the risk of gout. Succinyl carnitine exhibited acceptable weak heterogeneity, and the results for other blood metabolites remained robust after sensitivity, heterogeneity, and pleiotropy testing. We conducted an enrichment analysis on potential blood metabolites, followed by a metabolic pathway analysis revealing four pathways associated with serum urate levels.ConclusionThe identified causal relationships between these metabolites and serum urate and gout offer a novel perspective, providing new mechanistic insights into serum urate levels and gout.

show abstract

Section: Introductionmentioning

confidence: 99%